NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) Given Average Rating of “Moderate Buy” by Brokerages

NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) has been assigned an average recommendation of “Moderate Buy” from the five research firms that are presently covering the stock, Marketbeat reports. One analyst has rated the stock with a sell rating, one has assigned a hold rating, two have assigned a buy rating and one has given a strong buy rating to the company. The average 1 year target price among brokerages that have covered the stock in the last year is $8.50.

Several research firms have recently issued reports on NRSN. Roth Mkm initiated coverage on shares of NeuroSense Therapeutics in a report on Tuesday. They set a “buy” rating and a $3.00 price objective on the stock. Wall Street Zen upgraded shares of NeuroSense Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, January 3rd. D. Boral Capital restated a “buy” rating and set a $14.00 price target on shares of NeuroSense Therapeutics in a research report on Monday. Finally, Weiss Ratings restated a “sell (e+)” rating on shares of NeuroSense Therapeutics in a report on Monday, December 29th.

Institutional Investors Weigh In On NeuroSense Therapeutics

Several institutional investors have recently bought and sold shares of NRSN. Squarepoint Ops LLC raised its stake in shares of NeuroSense Therapeutics by 91.0% during the third quarter. Squarepoint Ops LLC now owns 95,375 shares of the company’s stock valued at $119,000 after purchasing an additional 45,450 shares in the last quarter. Jane Street Group LLC bought a new position in shares of NeuroSense Therapeutics during the second quarter worth approximately $54,000. Two Sigma Investments LP bought a new position in shares of NeuroSense Therapeutics during the 3rd quarter worth approximately $26,000. Finally, Yorkville Advisors Global LP bought a new position in shares of NeuroSense Therapeutics in the fourth quarter worth approximately $77,000. 1.04% of the stock is currently owned by hedge funds and other institutional investors.

NeuroSense Therapeutics Stock Down 3.0%

NRSN opened at $0.84 on Tuesday. The firm’s 50-day simple moving average is $0.92 and its 200-day simple moving average is $1.03. NeuroSense Therapeutics has a twelve month low of $0.68 and a twelve month high of $2.60.

About NeuroSense Therapeutics

NeuroSense Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapies for neurodegenerative and age-related neurological disorders. The company’s primary mission is to address unmet medical needs in diseases characterized by protein aggregation, chronic inflammation and cellular senescence in the central nervous system.

At the core of NeuroSense’s approach is a proprietary senotherapeutic platform designed to selectively target and clear senescent cells that contribute to neurodegeneration.